Have you or someone you love been diagnosed with stage 4 PD-L1 high non-small cell lung cancer (NSCLC) that has never been treated?
If so, there is a phase 3 clinical trial called HARMONi-7 that you may want to ask your doctor about.
HARMONi-7 is a randomized, double-blinded, global Phase 3 study of ivonescimab versus pembrolizumab for the first-line treatment of metastatic non-small cell lung cancer in patients whose tumors have high PD-L1 levels.
Please contact your doctor
or email medinfo@smmttx.com for more information.
What is the purpose of this clinical trial?
- The purpose of this trial is to learn whether a new investigational treatment called ivonescimab will work and be safe for the treatment of NSCLC that has spread. The study will compare the investigational treatment with an approved treatment called pembrolizumab.
What is the clinical trial drug, ivonescimab?
- Ivonescimab is an investigational treatment, which works by blocking two separate targets in the body to decrease the cancer cells’ ability to live, grow, and spread.
Your Doctor can provide you with additional information but here are a few things to know:
- If you are eligible, what is involved? Once enrolled in the clinical trail, you will visit the clinic every three weeks for infusions. The treatment may continue for up to 24 months.
- You will receive regular blood tests and scans of your tumor.
- You will be regularly asked about any side effects or safety concerns you have, including worsening symptoms of previous illness.
If you are in the clinical trial, will you receive ivonescimab?
- You will be randomly assigned to one of two treatment groups.
- Half the patients will be assigned to receive ivonescimab and the other half will receive pembrolizumab.
- Ivonescimab or pembrolizumab is administered by infusion (medication delivered into the body through the bloodstream instead of taking as pills or liquid)
Ivonescimab is an investigational therapy that is not presently approved by
any regulatory authority other than China’s National Medical Products Administration (NMPA).
